Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

Article summary

Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory Patients REHOVOT, Israel, Oct. 28, 2026 — Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry...